Johnson & Johnson Services, INC.
Healthcare company.
Based in DC
🤖
AI Overview
With $1.4M in lobbying spend across 29 quarterly filings, Johnson & Johnson Services, INC. is a significant lobbying presence.
$1.4M
Total Lobbying Spend
29
Quarterly Filings
1
Lobbying Firms Used
8
Individual Lobbyists
Spending by Year
| Year | Lobbying Spend |
|---|---|
| 2019 | $100K |
| 2020 | $250K |
| 2021 | $200K |
| 2022 | $200K |
| 2023 | $170K |
| 2024 | $200K |
| 2025 | $260K |
Lobbying Firms
THE NICKLES GROUP, LLC
What They Lobby For
- Issues related to drug pricing.
- Issues related to drug pricing and transparency; issues related to S. 1895, Lower Health Care Costs Act of 2019; S. 340, CREATES Act of 2019; issues related to the regulation of cosmetics.
- Issues related to biosimilars; H.R. 2296, the METRIC Act; S. 2543, Prescription Drug Pricing Reduction Act of 2019, issues related to ASP reporting.
- H.R. 1158, the Consolidated Appropriations Act of 2020 and H.R. 1865, Further Consolidated Appropriations Act, 2020.
- Issues related to biosimilars; H.R. 2296, the METRIC Act; S. 2543, Prescription Drug Pricing Reduction Act of 2019, issues related to ASP reporting; H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act.
- Issues related to biosimilars; S. 2543, Prescription Drug Pricing Reduction Act of 2019, issues related to ASP reporting; H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act.
- Issues related to drug pricing and transparency; issues related to S. 1895, Lower Health Care Costs Act of 2019; S. 340, CREATES Act of 2019; issues related to the regulation of cosmetics; monitored issues related to P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); issues related to maternal mortality.
- Issues related to drug pricing; monitored issues related to S. 1895, Lower Health Care Costs Act of 2019; monitored issues related to P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); issues related to maternal mortality; issues related to vaccines and liability.
- Monitored issues related to biosimilars; S. 2543, Prescription Drug Pricing Reduction Act of 2019, issues related to ASP reporting.
- Monitored issues related to H.R. 7120, the George Floyd Justice in Policing Act, and S. 3985, the JUSTICE Act.
Related Investigations
Big Pharma's $452M Lobbying Machine
How pharmaceutical companies spend hundreds of millions to influence health policy.
The 2025 Tariff Panic
As tariffs return, lobbying on trade surges.
Federal Lobbying Statistics 2025
The definitive stats — $15.2B total, industry breakdowns, and trends.
What Is Lobbying? A Complete Guide
How lobbying works, who does it, and why it matters.
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.